Why the study?
It is timely to evaluate the utility and practicability of genomic screening for malignant hyperthermia susceptibility to address what would be needed to end deaths from malignant hyperthermia.
Key points are not available for this paper at this time.
Design
Review
Should not yet alter MH screening; leaves open whether genomic pathway prevents deaths.
It is timely to consider the utility and practicability of screening for malignant hyperthermia susceptibility using genomic testing. Here the authors pose a simple, but bold question: what would it take to end deaths from malignant hyperthermia? The authors review recent advances and propose a scientific and clinical pathway toward this audacious goal to provoke discussion in the field.
No takes yet. Share an insight, caveat, or question.
Biesecker et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: